Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: A meta-analysis of clinical studies

Clinical Pharmacokinetics

Volumn 51, Issue 4, 2012, Pages 225-236

  Bellmann, Romuald ^a   Feistritzer, Clemens ^a   Wiedermann, Christian J ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

Metabolic clearance rate; Pharmacokinetics; Pharmacology; Plasma expanders; Plasma substitutes.

Indexed keywords

HETASTARCH;

CONCENTRATION (PARAMETERS); DATA BASE; HUMAN; MEDICAL LITERATURE; MOLECULAR WEIGHT; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; SUBSTITUTION REACTION; URINARY EXCRETION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HETASTARCH; HUMANS; INFUSIONS, INTRAVENOUS; MOLECULAR WEIGHT; PLASMA SUBSTITUTES; TISSUE DISTRIBUTION;

EID: 84858192562     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11594700-000000000-00000     Document Type: Review

References (60)

1. Schortgen F, Deye N, Brochard L. Preferred plasma volume expanders for critically ill patients: Results of an international survey. Intensive Care Med 2004 Dec; 30 (12): 2222-9
2. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004 May; 139 (5): 552-63
3. Bork K. Pruritus precipitated by hydroxyethyl starch: A review. Br J Dermatol 2005 Jan; 152 (1): 3-12
4. Pfeifer U, Kult J, Förster H. Ascites als Komplikation hepatischer Speicherung von Hydroxyethylstärke (HES) bei Langzeitdialyse. Klin Wochenschr 1984 Sep 17; 62 (18): 862-6
5. Schmidt-Hieber M, Loddenkemper C, Schwartz S, et al. Hydrops lysosomalis generalisatus - an underestimated side effect of hydroxyethyl starch therapy? Eur J Haematol 2006 Jul; 77 (1): 83-5
6. Westphal M, James MF, Kozek-Langenecker S, et al. Hydroxyethyl starches: Different products - different effects. Anesthesiology 2009 Jun 8; 111 (1): 187-202
7. Ferber HP, Nitsch E, Förster H. Studies on hydroxyethyl starch: Part II. Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers. Arzneimittelforschung 1985; 35 (3): 615-22
8. Treib J, Haass A, Pindur G, et al. HES 200/0.5 is not HES 200/0.5: Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74 (6): 1452-6
9. Thompson WL, Fukushima T, Rutherford RB, et al. Intravascular persistence, tissue storage, and excretion of hydroxyethyl starch. Surg Gynecol Obstet 1970 Nov; 131 (5): 965-72
10. Lindblad G, Falk J. Konzentrationsverlauf von Hydroxyäthylstä rke und Dextran in Serum und Lebergewebe von Kaninchen und die histopathologischen Folgen der Speicherung von Hydroxyäthylstärke. Infusionstherapie 1976; 3 (5): 301-3
11. Paulini K, Sonntag W. Veränderungen des RHS der Ratte nach parenteraler Gabe von Dextran (Mw 40000) und Hydroxyäthylstärke (Mw 40000): Chemische, licht- und elektronenmikroskopische Untersuchungen. Infusionstherapie 1976; 3 (5): 294-9
12. Jesch F, Hübner G, Zumtobel V, et al. Hydroxyäthylstärke (HÄS 450/0,7) in Plasma und Leber: Konzentrationsverlauf und histologische Veränderungen beim Menschen. Infusionsther Klin Ernahr 1979 Apr; 6 (2): 112-7
13. Förster H, Wicarkzyk C, Dudziak R. Bestimmung der Plasmaelimination von Hydroxyaethylstärke und von Dextran mittels verbesserter analytischer Methodik. Infusionstherapie 1981 Apr; 2 (2): 88-94
14. Jungheinrich C, Scharpf R, Wargenau M, et al. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 2002 Sep; 95 (3): 544-51
15. Waitzinger J, Bepperling F, Pabst G, et al. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: Pharmacokinetics and safety after multiple infusions of 10%solution in healthy volunteers. Drugs RD2003; 4 (3): 149-57
16. Kalhorn TF, Yacobi A, Sum CY. Biliary excretion of hydroxyethyl starch in man. Biomed Mass Spectrom 1984 Apr; 11 (4): 164-6
17. Lenz K, Schimetta W, Pölz W, et al. Intestinal elimination of hydroxyethyl starch? Intensive Care Med 2000 Jun; 26 (6): 733-9
18. Sirtl C, Laubenthal H, Zumtobel V, et al. Tissue deposits of hydroxyethyl starch (HES): Dose-dependent and time-related. Br J Anaesth 1999 Apr; 82 (4): 510-5
19. Ständer S, Szépfalusi Z, Bohle B, et al. Differential storage of hydroxyethyl starch (HES) in the skin: An immunoelectron-microscopical long-term study. Cell Tissue Res 2001 May; 304 (2): 261-9
20. Nohé B, Burchard M, Zanke C, et al. Endothelial accumulation of hydroxyethyl starch and functional consequences on leukocyte-endothelial interactions. Eur Surg Res 2002 Sep-Oct; 34 (5): 364-72
21. Asskali F, Förster H. Zur Kumulation unterschiedlich substituierter Hydroxyethylstärke (HES) nach repetitiver Infusion bei gesunden Versuchspersonen. Anästhesiol Intensivmed Notfallmed Schmerzther 1999 Sep; 34 (9): 537-41
22. Ballinger 2nd WF, Murray GF, Morse EE. Preliminary report on the use of hydroxyethyl starch solution in man. J Surg Res 1966 Apr; 6 (4): 180-3
23. Lee Jr WH, Cooper N, Weidner Jr MG, et al. Clinical evaluation of a new plasma expander hydroxyethyl starch. J Trauma 1968 May; 8 (3): 381-93
24. Solanke TF. Clinical trial of 6 per cent hydroxyethyl starch (a new plasma expander). Br Med J 1968 Sep 28; 3 (621): 783-5
25. Metcalf W, Papadopoulos A, Tufaro R, et al. A clinical physiologic study of hydroxyethyl starch. Surg Gynecol Obstet 1970 Aug; 131 (2): 255-67
26. Mishler JM, Borberg H, Emerson PM, et al. Hydroxyethyl starch: An agent for hypovolemic shock treatment. I: Serum concentrations in normal volunteers following three consecutive daily infusions. J Surg Res 1977 Oct; 23 (4): 239-45
27. Mishler JM, Borberg H, Emerson PM, et al. Hydroxyethyl starch: An agent for hypovolaemic schock treatment. II: Urinary excretion in normal volunteers following three consecutive daily infusions. Br J Clin Pharmacol 1977 Oct; 4 (5): 591-5
28. Mishler IV JM, Parry ES, Petrie A, et al. Plasma clearance and renal excretion of erythrocyte cryoprotectant hydroxyethylated amylopectin. Br J Haematol 1978 Oct; 40 (2): 231-7
29. Mishler JM, Parry ES, Sutherland BA, et al. A clinical study of low molecular weight-hydroxyethyl starch, a new plasma expander. Br J Clin Pharmacol 1979 Jun; 7 (6): 619-22
30. Mishler JM, Ricketts CR, Parkhouse EJ, et al. Catabolism of low-molecularweight hydroxyethylated amylopectin in man: I. Changes in the circulating molecular composition. J Lab Clin Med 1979 Dec; 94 (6): 841-7
31. Mishler IV JM. Pharmakokinetik mittelmolekularer Hydroxyä thylstärke (HÄS 200/0,5). Infusionsther Klin Ernahr 1980 Apr; 7 (2): 96-102
32. Mishler JM, Ricketts CR, Parkhouse EJ, et al. The catabolism of low molecular weight-hydroxyethylated amylopectin in man: II. Changes in the urinary molecular profiles. Int J Clin Pharmacol Ther Toxicol 1980 Jan; 18 (1): 5-9
33. Mishler JM, Ricketts CR, Parkhouse EJ. Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man. J Clin Pathol 1981 Apr; 34 (4): 361-5
34. Köhler H, Zschiedrich H, Linfante A, et al. Die Elimination von Hydroxyäthylstärke 200/0,5, Dextran 40 und Oxypolygelatine. Klin Wochenschr 1982 Mar; 60 (6): 293-301
35. Köhler H, Zschiedrich H, Clasen R, et al. Blutvolumen, kolloidosmotischer Druck und Nierenfunktion von Probanden nach Infusion mittelmolekularer 10% Hydroxyäthylstärke 200/0,5 und 10% Dextran 40. Anaesthesist 1982 Feb; 31 (2): 61-7
36. Yacobi A, Stoll RG, Sum CY, et al. Pharmacokinetics of hydroxyethyl starch in normal subjects. J Clin Pharmacol 1982 Apr; 22 (4): 206-12
37. Korttila K, Gröhn P, Gordin A, et al. Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol 1984 Jul; 24 (7): 273-82
38. Waitzinger J, Bepperling F, Pabst G, et al. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] after singledose infusion of 6%or 10%solutions in healthy volunteers. Clin Drug Investig 1998; 16 (2): 151-60
39. Asskali F, Warnken U, Förster H. Acetylstärke als Volumenersatz, eine mö- gliche Alternative zu HES. Dtsch Med Wochenschr 2001 Jan 5; 126 (1-2): 1-6
40. Förster H, Lehmann G, Asskali F. Das in vivo mittlere Molekular-gewicht und die Nierenschwelle von Hydroxyethylstärke am Beispiel mittelsubstituierter HES (HES 70/0,5). Anästhesiol Intensivmed Notfallmed Schmerzther 2001 Jan; 36 (1): 31-7
41. Wilkes NJ, Woolf RL, Powanda MC, et al. Hydroxyethyl starch in balanced electrolyte solution (Hextend™) - pharmacokinetic and pharmacodynamic profiles in healthy volunteers. Anesth Analg 2002 Mar; 94 (3): 538-44
42. Lehmann G, Asskali F, Förster H. Pharmacokinetics of hydroxyethyl starch (70/0.5) following repeated infusions. Transfus Med Hemother 2003 Mar; 30 (2): 72-7
43. Lesch A. Hydroxyethylstärke (HES) im Urin nach Mehrfachinfusion von HES (450/0,7): Physiko-chemische Veränderungen der Substanzcharakteristika einer hochsubstituierten, hochmolekularen HES [dissertation]. Frankfurt: Johann Wolfgang Goethe-Universität, 2003
44. Lehmann GB, Asskali F, Boll M, et al. HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br J Anaesth 2007 May; 98 (5): 635-44
45. Lehmann G, Marx G, Förster H. Bioequivalence comparison between hydroxyethyl starch 130/0.42/6:1 and hydroxyethyl starch 130/0.4/9:1. Drugs R D 2007; 8 (4): 229-40
46. Bogan RK, Gale GR, Walton RP. Fate of 14C-labeled hydroxyethyl starch in animals. Toxicol Appl Pharmacol 1969; 15 (1): 206-11
47. Eisenbach C, Schönfeld AH, Vogt N, et al. Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: Influence of molecular weight and degree of substitution. Intensive Care Med 2007 Jun 7; 33 (9): 1637-44
48. Lukasewitz P, Kroh U, Löwenstein O, et al. Quantitative Untersuchungen zur Gewebsspeicherung von mittelmolekularer Hydroxyethylstä rke 200/0,5 bei Patienten mit Multiorganversagen. J Anaesth Intensivbeh 1998; 3 (3): 42-6
49. Cittanova ML, Leblanc I, Legendre C, et al. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996 Dec 14; 348 (9042): 1620-2
50. de Labarthe A, Jacobs F, Blot F, et al. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med 2001 Oct 1; 111 (5): 417-8
51. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: Acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008 Mar; 51 (3): 491-503
52. Kiehl P, Metze D, Kresse H, et al. Decreased activity of acid a-glucosidase in a patient with persistent periocular swelling after infusions of hydroxyethyl starch. Br J Dermatol 1998 Apr; 138 (4): 672-7
53. Metze D, Reimann S, Szepfalusi Z, et al. Persistent pruritus after hydroxyethyl starch infusion therapy: A result of long-term storage in cutaneous nerves. Br J Dermatol 1997 Apr; 136 (4): 553-9
54. Christidis C, Mal F, Ramos J, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001 Dec; 35 (6): 726-32
55. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: A meta-analysis of postoperative bleeding. Ann Thorac Surg 2001 Aug; 72 (2): 527-33
56. Wiedermann CJ. Hydroxyethyl starch - can the safety problems be ignored? Wien Klin Wochenschr 2004 Sep 30; 116 (17-18): 583-94
57. Davidson IJ. Renal impact of fluid management with colloids: A comparative review. Eur J Anaesthesiol 2006 Sep; 23 (9): 721-38
58. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008 Jan 24; 8 (1): 1-8
59. Zarychanski R, Turgeon AF, Fergusson DA, et al. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: Systematic review and meta-analysis of randomized trials. Open Med 2009; 3 (4): E196-209
60. Dart AB, Mutter TC, Ruth CA, et al. Hydroxyethyl starch (HES) versus other fluid therapies: Effects on kidney function. Cochrane Database Syst Rev 2010; (1): CD007594